中国神经再生研究(英文版) ›› 2019, Vol. 14 ›› Issue (6): 971-972.doi: 10.4103/1673-5374.250573

• 观点:神经损伤修复保护与再生 • 上一篇    下一篇

新合成的包含芳基哌嗪片段的8-氨基葡萄糖衍生物的神经保护和MAO-B抑制作用的体外评价

  

  • 出版日期:2019-06-15 发布日期:2019-06-15

Preliminary in vitro evaluation of neuroprotective and monoamine oxidase type B inhibitory effects of newly synthesized 8-aminocaffeines

Magdalena Kondeva-Burdina1 , Maya Georgieva2, Alexandra Kasabova-Angelova1, Virginia Tzankova1, Alexander Zlatkov2   

  1. 1 Laboratory of Drug Metabolism and Drug Toxicity, Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria;
    2 Department of Pharmaceutical chemistry, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria
  • Online:2019-06-15 Published:2019-06-15
  • Contact: Magdalena Kondeva-Burdina, PhD, magdalenakondeva@gmail.com.

Abstract:

The expected growth of the elderly population at highest risk for Parkinson’s disease (PD) in the next decades makes the identification of factors that promote or prevent the disease an important goal. In addition, new therapies - aiming to delay the progression of PD are also needed. However, there have been few clinical trials designed to investigate neuroprotection. Thus the application of an appropriate in vitro model such as the neuroblastoma SH-SY5Y cell line is extremely helpful. These cells were selected due to its human origin, catecholaminergic neuronal properties, and ease of maintenance.